Multiple hydrogen bonding driven supramolecular architectures and their biomedical applications

Y Liu, L Wang, L Zhao, Y Zhang, ZT Li… - Chemical Society …, 2024 - pubs.rsc.org
Supramolecular chemistry combines the strength of molecular assembly via various
molecular interactions. Hydrogen bonding facilitated self-assembly with the advantages of …

Insulin receptor isoforms in physiology and disease: an updated view

A Belfiore, R Malaguarnera, V Vella… - Endocrine …, 2017 - academic.oup.com
The insulin receptor (IR) gene undergoes differential splicing that generates two IR isoforms,
IR-A and IR-B. The physiological roles of IR isoforms are incompletely understood and …

The emerging role of RNA as a therapeutic target for small molecules

CM Connelly, MH Moon, JS Schneekloth - Cell chemical biology, 2016 - cell.com
Recent advances in understanding different RNAs and unique features of their biology have
revealed a wealth of information. However, approaches to identify small molecules that …

Small molecule approaches to targeting RNA

S Kovachka, M Panosetti, B Grimaldi… - Nature Reviews …, 2024 - nature.com
The development of innovative methodologies to identify RNA binders has attracted
enormous attention in chemical biology and drug discovery. Although antibiotics targeting …

MBNL proteins and their target RNAs, interaction and splicing regulation

P Konieczny, E Stepniak-Konieczna… - Nucleic acids …, 2014 - academic.oup.com
Muscleblind-like (MBNL) proteins are key regulators of precursor and mature mRNA
metabolism in mammals. Based on published and novel data, we explore models of tissue …

Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1

L Nguyen, LM Luu, S Peng, JF Serrano… - Journal of the …, 2015 - ACS Publications
Single-agent, single-target therapeutic approaches are often limited by a complex disease
pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type …

A designed small molecule inhibitor of a non-coding RNA sensitizes HER2 negative cancers to herceptin

MG Costales, DG Hoch, D Abegg… - Journal of the …, 2019 - ACS Publications
A small molecule (1) with overlap** affinity for two microRNA (miRNA) precursors was
used to inform design of a dimeric compound (2) selective for one of the miRNAs. In …

Synthetic small-molecule RNA ligands: future prospects as therapeutic agents

A Di Giorgio, M Duca - MedChemComm, 2019 - pubs.rsc.org
RNA is one of the most intriguing and promising biological targets for the discovery of
innovative drugs in many pathologies and various biologically relevant RNAs that could …

Using genome sequence to enable the design of medicines and chemical probes

AJ Angelbello, JL Chen, JL Childs-Disney… - Chemical …, 2018 - ACS Publications
Rapid progress in genome sequencing technology has put us firmly into a postgenomic era.
A key challenge in biomedical research is harnessing genome sequence to fulfill the …

Insights into the development of chemical probes for RNA

BS Morgan, JE Forte, AE Hargrove - Nucleic Acids Research, 2018 - academic.oup.com
Over the past decade, the RNA revolution has revealed thousands of non-coding RNAs that
are essential for cellular regulation and are misregulated in disease. While the development …